Skip to Content

Notice

Certain Bone Cements, Components Thereof and Products Containing the Same; Institution of Investigation

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

U.S. International Trade Commission.

ACTION:

Notice.

SUMMARY:

Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on March 5, 2019, under section 337 of the Tariff Act of 1930, as amended, on behalf of Heraeus Medical LLC of Yardley, Pennsylvania and Heraeus Medical GmbH of Germany. A letter amending the complaint was filed on March 22, 2019. The complaint alleges violations of section 337 based upon the importation into the United States, and in the sale of certain bone cements, components thereof and products containing the same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry in the United States or to prevent the establishment of such an industry.

The complainants request that the Commission institute an investigation Start Printed Page 14395and, after the investigation, issue a limited exclusion order and cease and desist orders.

ADDRESSES:

The complaint, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Room 112, Washington, DC 20436, telephone (202) 205-2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205-2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Pathenia M. Proctor, The Office of Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205-2560.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Start Authority

Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission's Rules of Practice and Procedure, 19 CFR 210.10 (2018).

End Authority

Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on April 4, 2019, ordered that

(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(A) of section 337 in the importation into the United States, or in the sale of certain bone cements, components thereof and products containing the same by reason of the misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure an industry in the United States or to prevent the establishment of such an industry;

(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is “(1) Biomet Bone Cement R, Refobacin® Bone Cement R and other bone cements designed and manufactured by the proposed Respondents; (2) the components of the accused bone cements products, which are the bone cement powder, liquid and the raw materials that comprise the powder and liquid; and (3) the ClearMixTM Vacuum Mixing Systems and accessories, the Compact Cement Vacuum Mixing Systems and MillerTM Cement Delivery Systems and accessories, the Optipac® mixing system, mixing bowls, plugs, bone preparation kits, molds, diagnostic kits, and other mixing and delivery systems made or sold by the proposed Respondents that contain or are used with the proposed Respondents' bone cements:”

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainants are:

Heraeus Medical LLC, 770 Township Line Road, Yardley, PA 19067.

Heraeus Medical GmbH, Philipp-Reis-Straße, 8-13, 61273 Wehrheim, Germany.

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:

Zimmer Biomet Holdings, Inc., 345 East Main Street, Warsaw, IN 46580.

Biomet, Inc., 56 East Bell Drive, Warsaw, IN 46582.

Zimmer Orthopaedic Surgical Products, Inc., 200 West Ohio Avenue, Dover, OH 44622.

Zimmer Surgical, Inc., 200 West Ohio Avenue, Dover, OH 44622.

Biomet France S.A.R.L., 58 Avenue de Lautagne, BP 75, Valence, 26903, France.

Biomet Deutschland GmbH, Gustav-Krone-Straße 2, 14167 Berlin, Germany.

Zimmer Biomet Deutschland GmbH, Merzhauser Str. 112, 79100 Freiburg im Breisgau, Germany.

Biomet Europe B.V., Toermalijnring 600, Dordrecht, 3316 LC, Netherlands.

Biomet Global Supply Chain Center B.V., Toermalijnring 600, Dordrecht, 3316 LC, Netherlands.

Zimmer Biomet Nederland B.V., Toermalijnring 600, Dordrecht, 3316 LC, Netherlands.

Biomet Orthopedics, LLC, 56 East Bell Drive, Warsaw, IN 46582.

Biomet Orthopaedics Switzerland GmbH, Riedstraße 6, Dietikon, 8953, Switzerland.

(c) The Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

Start Signature

By order of the Commission.

Issued: April 5, 2019.

Lisa Barton,

Secretary to the Commission.

End Signature End Supplemental Information

[FR Doc. 2019-07102 Filed 4-9-19; 8:45 am]

BILLING CODE 7020-02-P